Granted Patent
B2
US 12,240,915 · App. 17/270,571 · Granted Mar 4, 2025
Chimeric antigen receptor cells for treating solid tumor
Inventors:
Lei Xiao (Rockville, MD); He Sun (Shanghai, CN); Zhiyuan Cao (Shanghai, CN); Wensheng Wang (Shanghai, CN); Chengfei Pu (Shanghai, CN); Li Mao (Shanghai, CN)
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.
Claims (23)
1. An antibody that binds ACPP, wherein the antibody comprises
(a) a light chain variable region (LVR) comprising amino acid sequence SEQ ID NO: 82 and a heavy chain variable region (HVR) comprising amino acid sequence SEQ ID NO: 83;
(b) an LVR comprising amino acid sequence SEQ ID NO: 84 and an HVR comprising amino acid sequence SEQ ID NO: 85;
(c) an LVR comprising amino acid sequence SEQ ID NO: 86, and an HVR comprising amino acid sequence SEQ ID NO: 87; or
(d) an LVR comprising amino acid sequence SEQ ID NO: 88 and an HVR comprising amino acid sequence SEQ ID NO: 89.
2. The antibody of claim 1 , wherein the HVR is joined to constant region of a human IgG, and the human IgG is IgG1 or IgG3.
3. The antibody of claim 1 , wherein the antibody is conjugated to a cytotoxic agent, and the cytotoxic agent is a radioactive isotope or a toxin.
4. The antibody of claim 1 , wherein the antibody comprises a scFv, and the LVR is connected to HVR via a linker.
5. The antibody of claim 4 , wherein the scFv comprises amino acid sequence SEQ ID NO: 173.
6. The antibody of claim 4 , wherein the scFv comprises amino acid sequences SEQ ID NOs: 82 and 83 that are joined by a linker.
7. A chimeric antigen receptor (CAR) comprising an antigen binding domain comprising the antibody of claim 5 , wherein the CAR comprises an extracellular domain, a transmembrane domain, and an intracellular domain, the extracellular domain comprising the antigen binding domain.
8. A chimeric antigen receptor (CAR) comprising an antigen binding domain comprising the antibody of claim 1 , wherein the CAR comprises an extracellular domain, a transmembrane domain, and an intracellular domain, the extracellular domain comprising the antigen binding domain.
9. The CAR of claim 7 , wherein the intracellular domain comprises a co-stimulatory signaling region that comprises an intracellular domain of a co-stimulatory molecule, and wherein the co-stimulatory molecule comprises CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, or a combination thereof.
10. A modified cell comprising the CAR of claim 7 .
11. The modified cell of claim 10 , wherein the modified cell is a T cell.
12. A polynucleotide that encodes the antibody of claim 5 .
13. A modified cell comprising the polynucleotide of claim 12 .
14. The modified cell of claim 13 , wherein the modified cell is a T cell.
15. The CAR of claim 8 , wherein the intracellular domain comprises a co-stimulatory signaling region that comprises an intracellular domain of a co-stimulatory molecule, and wherein the co-stimulatory molecule comprises CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, or a combination thereof.
16. A modified cell comprising the CAR of claim 15 .
17. A polynucleotide encoding the antibody of claim 1 .
18. A modified cell comprising the polynucleotide of claim 17 .
19. The modified cell of claim 18 , wherein the modified cell is a T cell.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 23, 2021
From: XIAO, LEI; SUN, HE; CAO, ZHIYUAN; WANG, WENSHENG; PU, CHENGFEI; MAO, LI
To: INNOVATIVE CELLULAR THERAPEUTICS CO., LTD.; INNOVATIVE CELLULAR THERAPEUTICS, INC.
Reel/Frame 055366/0244 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 23, 2021
From: INNOVATIVE CELLULAR THERAPEUTICS CO., LTD.
To: INNOVATIVE CELLULAR THERAPEUTICS HOLDINGS, LTD.
Reel/Frame 055366/0460 →
Continuity (7)
Provisional Application
62848984
· May 16, 2019
Provisional Application
62842936
· May 3, 2019
Provisional Application
62807482
· Feb 19, 2019
Provisional Application
62754175
· Nov 1, 2018
Provisional Application
62731079
· Sep 13, 2018
Provisional Application
62725025
· Aug 30, 2018
References Cited (253)
US 9388237B2
· Govindan
· 2016
[cited by applicant]
US 9572837B2
· Wu
· 2017
[cited by applicant]
US 9932405B2
· Xiao et al.
· 2018
[cited by applicant]
US 20050079170A1
· Le Gall et al.
· 2005
[cited by applicant]
US 20130108609A1
· Vihko
· 2013
[cited by applicant]
US 20160024175A1
· Chow et al.
· 2016
[cited by applicant]
US 20160250258A1
· Delaney et al.
· 2016
[cited by applicant]
US 20170015746A1
· Jensen
· 2017
[cited by applicant]
US 20170136063A1
· Perez et al.
· 2017
[cited by applicant]
US 20170145108A1
· Schreiber et al.
· 2017
[cited by applicant]
US 20170209492A1
· June et al.
· 2017
[cited by applicant]
US 20170224798A1
· Cooper et al.
· 2017
[cited by applicant]
US 20170319638A1
· Conner et al.
· 2017
[cited by applicant]
US 20170335281A1
· Loew et al.
· 2017
[cited by applicant]
US 20170362325A1
· Jung et al.
· 2017
[cited by applicant]
US 20180028631A1
· Chen
· 2018
[cited by applicant]
US 20180223255A1
· Wu et al.
· 2018
[cited by applicant]
US 20180243340A1
· Varadarajan et al.
· 2018
[cited by applicant]
US 20180334490A1
· Brogdon et al.
· 2018
[cited by applicant]
US 20210060069A1
· Xiao et al.
· 2021
[cited by applicant]
US 20210137983A1
· Xiao et al.
· 2021
[cited by applicant]
US 20210161961A1
· Xiao et al.
· 2021
[cited by applicant]
US 20210379149A1
· Pu et al.
· 2021
[cited by applicant]
US 20220000921A1
· Xiao et al.
· 2022
[cited by applicant]
US 20220096546A1
· Xiao et al.
· 2022
[cited by applicant]
US 20220339193A1
· Xiao et al.
· 2022
[cited by applicant]
US 20230312677A1
· Posey et al.
· 2023
[cited by applicant]
EP 2508176A1
· 2012
[cited by applicant]
JP 2016500659A1
· 2016
[cited by applicant]
JP 2018508539A
· 2018
[cited by applicant]
JP 2018518939A
· 2018
[cited by applicant]
JP 2018528774A
· 2018
[cited by applicant]
JP 2021510540A
· 2021
[cited by applicant]
JP 2022507830A
· 2022
[cited by applicant]
NO 168969B
· 1992
[cited by applicant]
WO WO8303679A1
· 1983
[cited by applicant]
WO WO2008131445
· 2008
[cited by applicant]
WO WO2010081738A1
· 2010
[cited by applicant]
WO WO2010126766A1
· 2010
[cited by applicant]
WO WO2012050374
· 2012
[cited by applicant]
WO WO2012066495A2
· 2012
[cited by applicant]
WO WO2012079000A1
· 2012
[cited by applicant]
WO WO2013123061A1
· 2013
[cited by applicant]
WO WO2014011984
· 2014
[cited by applicant]
WO WO2014011988A2
· 2014
[cited by applicant]
WO WO2015157384A1
· 2015
[cited by applicant]
WO WO2015157432A1
· 2015
[cited by applicant]
WO WO2016061574A1
· 2016
[cited by applicant]
WO WO2016070136
· 2016
[cited by applicant]
WO WO2016090034A2
· 2016
[cited by applicant]
WO WO2016090190A1
· 2016
[cited by applicant]
WO WO2016113203
· 2016
[cited by applicant]
WO WO2016164731A2
· 2016
[cited by applicant]
WO WO2016174652A1
· 2016
[cited by applicant]
WO WO2016210293
· 2016
[cited by applicant]
WO WO2017011804A1
· 2017
[cited by applicant]
WO WO2017027291A1
· 2017
[cited by applicant]
WO WO2017050884
· 2017
[cited by applicant]
WO WO2017075537A1
· 2017
[cited by applicant]
WO WO2017120525A1
· 2017
[cited by applicant]
WO WO2017040324
· 2017
[cited by applicant]
WO WO2017149515
· 2017
[cited by applicant]
WO WO2017167217A1
· 2017
[cited by applicant]
WO WO2017172952A1
· 2017
[cited by applicant]
WO WO2017172981
· 2017
[cited by applicant]
WO WO2017173403
· 2017
[cited by applicant]
WO WO2017177137
· 2017
[cited by applicant]
WO WO2017210617A2
· 2017
[cited by applicant]
WO WO2018013918
· 2018
[cited by applicant]
WO WO2018018958
· 2018
[cited by applicant]
WO WO2018023976A1
· 2018
[cited by applicant]
WO WO2018027155
· 2018
[cited by applicant]
WO WO2018049418
· 2018
[cited by applicant]
WO WO2018067697
· 2018
[cited by applicant]
WO WO2018106732A1
· 2018
[cited by applicant]
WO WO2018111763A1
· 2018
[cited by applicant]
WO WO2019091478
· 2019
[cited by applicant]
WO WO2019136305A1
· 2019
[cited by applicant]
WO WO2019140100A1
· 2019
[cited by applicant]
WO WO2019178576A1
· 2019
[cited by applicant]
WO WO2020086742
· 2020
[cited by applicant]
WO WO2020086989A1
· 2020
[cited by applicant]
WO WO2020106843A1
· 2020
[cited by applicant]
WO WO2020146743A1
· 2020
[cited by applicant]
Priceman, Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA + metastatic prostate cancer. Oncoimmunology (2018) vol. 7 Issue 2, 1-13. (Published Online 2017) (Ye…
[cited by examiner]
Brown et al. Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR2: a means of minimizing B cell wastage from somatic hypermutation. J Immunol (1996) 156(9):3285-3291. (Year: 1996).
[cited by examiner]
Almagro et al. Progress and challenges in the design and clinical development of antibodies for cancer therapy. Fronteirs in Immunology (2018) 8:1751. (Year: 2018).
[cited by examiner]
Kong et al. Emerging Roles of Human Prostatic Acid Phosphatase. 2013. Biomol Ther. 21(1): 10-20. (Year: 2013).
[cited by examiner]
Brischwein et al. “Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class” J Immunother, Nov. 2007, vol. 30, pp. 798-807.
[cited by applicant]
Chmielewski, “Of CARs and TRUCKs: Chimeric antigen receptor (CAR) T Cells Engineered with an Inducible Cytokine to Modulate the Tumor Stroma,” Jan. 2014. Imunological Reviews, 257(1): 83-90.
[cited by applicant]
European Search Report mailed Aug. 31, 2021 in European Application No. 21275039.2, a foreign corresponding application of U.S. Appl. No. 16/999,357, 13 pages.
[cited by applicant]
Huang et al., “Interleukin-armed Chimeric Antigen Receptor-modified T Cells for Cancer Immunotherapy,” Sep. 2017. Gene Thereapy, 25(3):192-197.
[cited by applicant]
International Preliminary Report on Patentability dated Jul. 22, 2021 in PCT Application No. PCT/US2020/013099, 9 pages.
[cited by applicant]
International Search Report & Written Opinion mailed Aug. 13, 2021 from PCT Application No. PCT/2021/028429, 12 pages.
[cited by applicant]
Lee et al., “Use of a Simgle CAR T Cell and Several Bispecific Adapters Facilitates Eradication of Multiple Antigenically Diffeerent Solid Tumors,” Nov. 2018. Cancer Research, 79(2): 387-396.
[cited by applicant]
Wong et al. “Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells,” Jun. 2013, Haematologica, vol. 98(12): 1930-1938.
[cited by applicant]
“Anti-ACPP Product Datasheet”, Atlas Antibodies, retrieved on Oct. 31, 2019 from https://www.atlasantibodies.com/api/print_datasheet/HPA004335.pdf, Dec. 2012 1 page.
[cited by applicant]
“Anti-UPK2 Product Datasheet”, Atlas Antibodies, retrieved on Oct. 31, 2019 from https://www.atlasantibodies.com/api/print_datasheet/HPA061106.pdf, Dec. 2012, 1 page.
[cited by applicant]
Invitation to Pay Additional Fees mailed on Nov. 13, 2019 for PCT Application PCT/US19/48890, 3 Pages.
[cited by applicant]
PCT Search Report and Written Opinion mailed on Feb. 7, 2020 for PCT Application No. PCT/US19/48890, 15 pages.
[cited by applicant]
European Office Action mailed Mar. 17, 2022 for European Patent Application No. 19700326.2, a foreign counterpart to U.S. Pat. No. 10,561,686, 7 pages.
[cited by applicant]
Partial European Search Report mailed May 4, 2022 for European Patent Application No. 19854895.0, 13 pages.
[cited by applicant]
Japanese office action mailed Apr. 5, 2022 in Japanese Application No. 2021-512204, a foreign correspondeing application of U.S. Appl. No. 17/220,387, 10 pages. Translated.
[cited by applicant]
Marks et al., “By-passing Immunization: Human Antibodies from V-gene Libraries Displayed on Phage” 1991. Journal of Molecular Biology, 222(3): 581-597.
[cited by applicant]
Canadian Office Action mailed Sep. 1, 2023 for Canadian Patent Application No. 3,125,646, a foreign counterpart to U.S. Pat. No. 10,869,888, 4 pages.
[cited by applicant]
Canadian Office Action mailed Jul. 20, 2022 for Canadian Patent Application No. 3,088,161, a foreign counterpart to U.S. Pat. No. 10,561,686, 4 pages.
[cited by applicant]
Chmielewski, et al., “IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster and Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Express…
[cited by applicant]
Extended European Search Report mailed Nov. 14, 2022 for European Patent Application No. 19887928.0, a foreign corresponding application of U.S. Appl. No. 16/445,965, 12 pages.
[cited by applicant]
Extended European Search Report mailed Nov. 24, 2022 for European Patent Application No. 20739064.2, a foreign corresponding application of U.S. Appl. No. 16/387,166, 13 pages.
[cited by applicant]
European Search Report mailed Aug. 4, 2022 in European Application No. 19854895.0, a foreign corresponding application of U.S. Appl. No. 17/270,571, 8 pages.
[cited by applicant]
Hoyos, et al., “Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety”, Leukemia, Apr. 2010, 24(6):1160-1170.
[cited by applicant]
Japanese Office Action mailed Sep. 20, 2022 for Japanese Patent Application No. 2020-558861, a foreign counterpart to U.S. Pat. No. 10,561,686, 7 pages.
[cited by applicant]
Klaver, et al., “Plasma IFN-[gamma] and IL-6 levels correlate with peripheral T-cell Nos. but not toxicity in RCC patients treated with CAR T-cells”, Clinical Immunology, Jul. 2016, 169:107-113.
[cited by applicant]
Koneru, et al., “IL-12 Secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo”, Oncoimmunology, Jan. 2015, 4(3):e994446, 11 pages.
[cited by applicant]
Posey et al., “Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma”, Immunity, Jun. 2016, 44(6):1444-1454.
[cited by applicant]
Leon-Triana, et al., “Dual-Target CAR-Ts with On- and Off-Tumor Activity May Override Immune Suppression in Solid Cancers: A Mathematical Proof of Concept”, Cancers, Feb. 2021, 13(4):703, 20 pages.
[cited by applicant]
Trinchieri, “Interleukin-12 and the regulation of innate resistance and adaptive immunity”, Nature Reviews Immunology, Feb. 2003, 3(2):133-146.
[cited by applicant]
Ghadially, et al., “Differential Regulation of CCL22 Gene Expression in Murine Dendritic Cells and B Cells”, The Journal of Immunology, May 2009, 174(9):5620-5629.
[cited by applicant]
Kim, et al., “Increased IL-12 inhibits B cells' differentiation to germinal center cells and promotes differentiation to short-lived plasmablasts”, The Journal of Experimental Medicine, Sep. 2008, 205(10):2437-2448.
[cited by applicant]
Largeot, et al., “The B-Side of Cancer Immunity: The Underrated Tune”, Cells, May 2019, 8(449):1-20.
[cited by applicant]
Bollino et al., “Chimeric Antigen Receptor-Engineered Natural Killer and Natural Killer T cells for Cancer Immunotherapy,” Translational Research, Jun. 2017, 187:32-43.
[cited by applicant]
Bork, P., “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,” Genome Research, 2000, 10:398-400.
[cited by applicant]
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,” Science, Mar. 1990, 247:1306-1310.
[cited by applicant]
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from its Receptor-binding Activities by Site-directed Mutagenesis of a Single…
[cited by applicant]
Cherkassky et al., “Human CAR T Cells with Cell-intrinsic PD-1 Checkpoint Blockade Resist Tumor-mediated Inhibition,” Journal of Clinical Investigation, May 2016, 126(8):3130-3144.
[cited by applicant]
Chmielewski et al., “CAR T Cells Releasing IL-18 Convert to T-Bethigh FoxO1low Effectors that Exhibit Augmented Activity Against Solid Tumors,” Cell Reports, Dec. 2017, 21:3205-3219.
[cited by applicant]
Duong et al., “Bacteria-cancer Interactions: Bacteria-based Cancer Therapy,” Experimental & Molecular Medicine, 2019, 51:152, 15 pages.
[cited by applicant]
Eyquem et al., “Targeting a CAR to the TRAC Locus with CRISPR/Cas9 Enhances Tumour Rejection,” Nature, Mar. 2017, 543:113-117.
[cited by applicant]
Fang et al., “NK Cell-based Immunotherapy for Cancer,” Seminars in Immunology, Aug. 2017, 31:37-54.
[cited by applicant]
Grada et al., “TanCar: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy,” Molecular Therapy—Nucleic Acids, Jul. 2013, vol. 2:e105, 11 pages.
[cited by applicant]
Japanese Office Action mailed May 30, 2023 for Japanese Patent Application No. 2020-558861, a foreign counterpart to U.S. Pat. No. 10,561,686, 7 pages.
[cited by applicant]
Lazar et al., “Transforming Growth Factor Alpha: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,” Mol. Cell. Biol., Mar. 1988, 8(3):1247-1252.
[cited by applicant]
Liu et al., “A Chimeric Switch-receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors,” Cancer Research, Mar. 2016, 76(6):1578-1590.
[cited by applicant]
Magee et al., “GUCY2C-directed CAR-T Cells Oppose Colorectal Cancer Metastases Without Autoimmunity,” Oncolmmunology, Oct. 2016, 5(1):e1227897, 11 pages.
[cited by applicant]
Mirzaei et al, “Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications,” Fronteirs in Immunology, Dec. 2017, 8:1850, 13 pages.
[cited by applicant]
Roybal et al., “Engineering T cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors,” Cell, Oct. 2016, 167:419-432.
[cited by applicant]
Sarvaria et al., “B cell Regulation in Cancer and Anti-Tumor Immunity”, Cellular and Molecular Immunology, Apr. 2017, 14:662-674.
[cited by applicant]
Singapore Office action mailed Feb. 28, 2023, in Singapore Application No. 11202107269X, a corresponding foreing application of U.S. Appl. No. 16/387,166, 12 pages.
[cited by applicant]
Turtle et al., “Immunotherapy of non-Hodgkin's Lymphoma with a Defined Ratio of CD8+ and CD4+ CD19-specific Chimeric Antigen Receptor-modified T cells,” Science Translational Medicine, Sep. 2016, 8:355: 29 pgs.
[cited by applicant]
Zhou et al, “The Use of tMUC1 Highly Specific Chimeric Antigen Receptor-redirected T cells for the Eradication of Triple Negative Breast Cancer,” J Immunol, May 2017, 198 (1 Supplement):198.10, 2 pages, Abstract.
[cited by applicant]
Canadian Office Action for Canadian Patent Appl.: 3,088,161, mailed Sep. 22, 2021, a foreign corresponding application of U.S. Appl. No. 16/999,357, 4 pages.
[cited by applicant]
Chen, et al., “CAR T-cell intrinsic PD-1 checkpoint blockade: a two-in-one approach for solid tumor immunotherapy,” Feb. 2017, Oncolmmunology, 6:2, e1273302, DOI: 10.1080/2162402X.2016.1273302. 4 pages.
[cited by applicant]
Extended European Search Report mailed Nov. 25, 2019 in EP Application No. 19180127.3, Xiao et al., a corresponding foreign application of U.S. Appl. No. 16/146,218, 11 pages.
[cited by applicant]
Fang et al., “Stable antibody expression at therapeutic levels using the 2A peptide,” May 2005, Nature Biotechnology. 23(5):584-590.
[cited by applicant]
PCT Communication Invitation to Pay Fees mailed Mar. 30, 2020 for PCT Application No. PCT/US20/13099, “Modified Cell Expansion and Uses Thereof”, 2 pages.
[cited by applicant]
Jernberg-Wiklund, et al., “Recombinant interferon-gamma inhibits the growth of IL-6-dependent human multiple myeloma cell lines in vitro,” 1991. Eur J Haematol, 46:231.239.
[cited by applicant]
Lee et al., “T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukemia in children and young adults: a phase 1 dose-escalation trial,” Oct. 2014. The Lancet, 385(9967): 517-528.
[cited by applicant]
Maude et al., “Chimeric antigen receptor T cells for sustained remissions in leukemia,” Oct. 2014. N Engl J Med. 371(16): 1507-1517.
[cited by applicant]
Milone, et al., “Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo,” Apr. 2009. Molecular Therapy, 17(8): 1453-1464.
[cited by applicant]
Partial European Search Report mailed Nov. 4, 2019 in EP Application No. 19180127.3, Xiao et al., a corresponding foreign application of U.S. Appl. No. 16/146,218, 18 pages.
[cited by applicant]
International Preliminary Report on Patentability mailed Mar. 11, 2021 for PCT Application No. PCT/US19/48890, 8 pages.
[cited by applicant]
International Search Report and Written Opinion mailed on Jun. 17, 2019 for PCT Application No. PCT/US19/13068, 14 pages.
[cited by applicant]
International Search Report and Written Opinion mailed on Feb. 20, 2020 for PCT Application No. PCT/US19/62417, 14 pages.
[cited by applicant]
International Search Report and Written Opinion mailed on Jun. 4, 2020 for PCT Application No. PCT/US2020/013099, 13 pages.
[cited by applicant]
Qin et al., “Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells,” 2017, Journal of Hematology & Oncology, 10:68, 11 pages.
[cited by applicant]
Sahm et al, “Expression of IL-15 in NK Cells Results in Rapid Enrichment and Selective Cytotoxicity of Gene-Modified Effectors That Carry a Tumor-Specific Antigen Receptor,” Sep. 2012, Cancer Immunol Immunother, 61(9): …
[cited by applicant]
Supplemental European Search Report mailed Jan. 13, 2020 in EP Application No. 19700326, Xiao et al., a corresponding foreign application of U.S. Appl. No. 16/146,218, 7 pages.
[cited by applicant]
Takahashi, et al, “Expression of MUC1 on myeloma cells and induction of HJLA-unrestricted CTL against MUC1 from a multiple myeloma patient,” 1994. J Immunol, 153:2102-2109.
[cited by applicant]
Wilkie, et al. “Retargeting of human T cells to tumor-associated MUC1: The evolution of a chimeric antigen receptor,” 2008, J. Immunol., 180:4901-4909.
[cited by applicant]
Xiao et al., “Pre-clinical experiments of cart cells identifying tshr as a potential target against metastatic thyroid cancer,” May 2018. Database EMBASE [Online] Elsevier Science Publishers, Database Accession No. EMB-…
[cited by applicant]
You et al., “Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated y modified Anti-MUC1 chimeric antigen receptor transduced T cells”, Apr. 2016, Science …
[cited by applicant]
U.S. Appl. No. 16/146,218, filed Sep. 28, 2018, US-2019-0216851-A1, U.S. Pat. No. 10,561,686, Granted.
[cited by applicant]
U.S. Appl. No. 16/961,418, filed Jul. 10, 2020, Pending.
[cited by applicant]
U.S. Appl. No. 16/445,965, filed Jun. 19, 2019, US-2020-0155598-A1, U.S. Pat. No. 10,918,667, Granted.
[cited by applicant]
U.S. Appl. No. 17/144,800, filed Jan. 8, 2021, US 2021-0161961 A1, Pending.
[cited by applicant]
U.S. Appl. No. 17/295,364, filed May 19, 2021, Pending.
[cited by applicant]
U.S. Appl. No. 16/387,166, filed Apr. 17, 2019, US 2019-0314411 A1, U.S. Pat. No. 10,869,888, Granted.
[cited by applicant]
U.S. Appl. No. 17/091,741, filed Nov. 6, 2020, US 2021-0137983 A1, Pending.
[cited by applicant]
U.S. Appl. No. 17/108,076, filed Dec. 1, 2020, US 2021-0077532 A1, Pending.
[cited by applicant]
U.S. Appl. No. 17/420,066, filed Jun. 30, 2021, Pending.
[cited by applicant]
U.S. Appl. No. 17/270,571, filed Feb. 23, 2021, Pending.
[cited by applicant]
U.S. Appl. No. 17/220,387, filed Apr. 1, 2021, Pending.
[cited by applicant]
U.S. Appl. No. 17/123,732, filed Dec. 16, 2020, Pending.
[cited by applicant]
U.S. Appl. No. 17/173,504, filed Feb. 11, 2021, Pending.
[cited by applicant]
U.S. Appl. No. 16/996,237, filed Aug. 18, 2020, US 2021-0060069 A1, Pending.
[cited by applicant]
U.S. Appl. No. 17/331,289, filed May 26, 2021, Pending.
[cited by applicant]
U.S. Appl. No. 16/999,357, filed Aug. 21, 2020, US 2021-0100841 A1, Pending.
[cited by applicant]
Rizzardi, et al., “Evaluation of Protein Biomarkers of Prostate Cancer Aggressiveness,” Dec. 2014. BMC Cancer, 14(1): 14 pgs.
[cited by applicant]
Altuntas et al., “Autoimmunity to Uroplakin II Causes Cystitis in Mice: A Novel Model of Interstitial Cystitis,” Eur Urol, Jan. 2012, 61(1):193-200.
[cited by applicant]
Auerbach et al., “Angiogenesis Assays: Problems and Pitfalls,” Cancer and Metastasis Reviews, Jun. 2000, 19:167-172.
[cited by applicant]
Beans, “Targeting Metastasis to Halt Cancer's Spread,” PNAS, Dec. 2018, 115(50):12539-12543.
[cited by applicant]
Canadian Office Action mailed Sep. 14, 2023 for Canadian Application No. 3120153, a foreign corresponding application of U.S. Appl. No. 17/295,364, 4 pages.
[cited by applicant]
Canadian Office Action mailed Sep. 19, 2023 for Canadian Application No. 3110096, a foreign corresponding application of U.S. Appl. No. 17/270,571, 3 pages.
[cited by applicant]
Gravanis et al., “The Changing World of Cancer Drug Development: The Regulatory Bodies' Perspective,” Chinese Clinical Oncology, May 2014, 3(2):22, 5 pages.
[cited by applicant]
Gura, “Systems for Identifying New Drugs Are Often Faulty,” Science, Nov. 1997, 278(5340):1041-1042.
[cited by applicant]
Hait, “Anticancer Drug Development: The Grand Challenges,” Nature Reviews/Drug Discovery, Apr. 2010, 9:253-254.
[cited by applicant]
Heppner et al., “Tumor Heterogeneity: Biological Implications and Therapeutic Consequences,” Cancer Metastasis Review 1983, 2:5-23.
[cited by applicant]
Hoang et al, “A Newly Developed Uroplakin II Antibody With Increased Sensitivity in Urothelial Carcinoma of the Bladder,” Arch Pathol Lab Med, Jul. 2014, 138:943-949.
[cited by applicant]
Jain, “Barriers to Drug Delivery in Solid Tumors,” Scientific American, Jul. 1994, 271(1):58-65.
[cited by applicant]
Japanese Office Action mailed Oct. 17, 2023 for Japanese Application No. 2021-527959, a foreign corresponding application of U.S. Appl. No. 17/295,364, 6 pages.
[cited by applicant]
Japanese Office Action mailed Oct. 31, 2023 for Japanese Application No. 2022-154638, aa foreign corresponding application of U.S. Appl. No. 17/270,571, 6 pages.
[cited by applicant]
Liou et al., “Macrophage-secreted Cytokines Drive Pancreatic Acinar-to-ductal Metaplasia Through NF-KB and MMPs,” Journal of Cell Biology, 2013, 202(3):563-577.
[cited by applicant]
Mishu et al., “Effects of Recombinant Canine Granulocyte Colony-stimulating Factor on White Blood Cell Production in Clinically Normal and Neutropenic Dogs,” J Am Vet Med Assoc., Jun. 1992, 200(12), Abstract, 1 page.
[cited by applicant]
Ping et al., “T-cell Receptor-engineered T Cells for Cancer Treatment: Current Status and Future Directions,” Protein Cell, Mar. 2018, 9(3):254-266.
[cited by applicant]
Rahman et al., “Histology, Natural Killer Cells,” retrieved from <<https://www.ncbi.nlm.nih.gov/books/NBK565844/>>, StatPearls Publishing, Feb. 2023, 6 pages.
[cited by applicant]
Rohaan et al., “Adoptive Cellular Therapies: The Current Landscape,” Virchows Archiv, Nov. 2018, 474:449-461.
[cited by applicant]
Snook et al., “GUCY2C-targeted Cancer Immunotherapy: Past, Present and Future,” Immunology Research, Dec. 2011, 51:161-169.
[cited by applicant]
Sporn et al., “Chemoprevention of Cancer”, Carcinogenesis, Mar. 2000, 21(3):525-530.
[cited by applicant]
Tigner et al., “Histology, White Blood Cell,” retrieved from <<https://www.ncbi.nlm.nih.gov/books/NBK563148/>>, StatPearls Publishing, Nov. 2022, 5 pages.
[cited by applicant]
Wu et al., “Potentiating Antilymphoma Efficacy of Chemotherapy Using a Liposome for Integration of CD20 Targeting, Ultra-violet Irradiation Polymerizing, and Controlled Drug Delivery”, Nanoscale Research Letters, 2014, …
[cited by applicant]
Yu et al., “CART Cell Therapy for Prostate Cancer: Status and Promise,” OncoTargets and Therapy, 2019, 12:391-395.
[cited by applicant]
Canadian Office Action mailed Oct. 25, 2023 for Canadian Application No. 3,088,161, a foreign counterpart to U.S. Pat. No. 10,561,686, 4 pages.
[cited by applicant]
Japanese Office Action mailed Jan. 16, 2024 for Japanese Application No. 2020-558861, a foreign counterpart to U.S. Pat. No. 10,561,686, 7 pages.
[cited by applicant]
Office Action for European Application No. 21275039.2, Dated May 23, 2024, 7 pages.
[cited by applicant]
Office Action for Japanese Application No. 2021-527959, Dated May 7, 2024, 6 pages.
[cited by applicant]
Kim, et al., “High Cleavage Efficiency of a 2A Peptide Derived from Porcine Teschovirus-1 in Human Cell Lines, Zebrafish and Mice”, PLoS One, vol. 6, issue 4, Apr. 29, 2011, pp. 1-8.
[cited by applicant]
Breloer et al., “CD83 Regulates Lymphocyte Maturation, Activation and Homeostasis,” Trends in Immunology, Mar. 2008, 29(4):186-194.
[cited by applicant]
Brudno et al., “Toxicities of Chimeric Antigen Receptor T Cells: Recognition and Management,” Blood, Jun. 2016, 127(26):3321-3330.
[cited by applicant]
Cho et al., “Triple Costimulation Via CD80, 4-1BB, and CD83 Ligand Elicits the Long-Term Growth of Vy9Vδ2 T Cells in Low Levels of IL-2,” Journal of Leukocyte Biology, Apr. 2016, 99(4):521-529.
[cited by applicant]
Du et al., “Granulocyte Colony-Stimulating Factor Treatment During Radiotherapy Is Associated With Survival Benefit in Patients With Lung Cancer,” Technology in Cancer Research & Treatment, Dec. 2018, 17:1-7.
[cited by applicant]
European Office Action mailed Feb. 5, 2024 for European Application No. 19854895.0, a foreign counterpart to U.S. Appl. No. 17/270,571, 6 pages.
[cited by applicant]
Japanese Office Action mailed Jan. 30, 2024 for Japanese Application No. 2021-540137, a foreign counterpart to U.S. Appl. No. 17/420,066, 7 pages.
[cited by applicant]
Konjevic et al., “The Role of Cytokines in the Regulation of NK Cells in the Tumor Environment,” Cytokine, May 2019, 117:30-40.
[cited by applicant]
Li et al., “CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential,” Frontiers in Immunology, Jun. 2019, 10:Article 1312, 9 pages.
[cited by applicant]
Rabinowich et al., “Response of Human NK Cells to IL-6 Alterations of the Cell Surface Phenotype, Adhesion to Fibronectin and Laminin, and Tumor Necrosis Factor-Alpha/Beta Secretion,” Journal of immunology, Jun. 1993, 1…
[cited by applicant]
Scheuermann et al., “CD19 Antigen in Leukemia and Lymphoma Diagnosis and Immunotherapy,” Leukemia & Lymphoma, 1995, 18(5-6):385-397.
[cited by applicant]
Su et al., “Interleukin-7 Expression and its Effect on Natural Killer Cells in Patients with Multiple Sclerosis,” J Neuroimmunol., Nov. 2014, 276(0):180-186.
[cited by applicant]
Zhang et al., “The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review,” Technology in Cancer Research & Treatment, Jul. 2019, 18:1-13.
[cited by applicant]